DI-ATRO

Post-LOE

atropine sulfate; diphenoxylate hydrochloride

NMD Pharma

ANDAORALTABLET

Approved

Apr 1977

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

DI-ATRO (atropine sulfate; diphenoxylate hydrochloride) by NMD Pharma is muscarine-like actions of acetyl-choline and is therefore classified as an antimuscarinic agent. Approved for older for: atropine is an anticholinergic agent indicated in adults, older for: cycloplegia () mydriasis () penalization of the healthy eye in the treatment of amblyopia () 1. First approved in 1977.

Drug data last refreshed 20h ago

Mechanism of Action

muscarine-like actions of acetyl-choline and is therefore classified as an antimuscarinic agent. Atropine is relatively selective for muscarinic receptors. Its potency at nicotinic receptors is much lower, and actions at non-muscarinic receptors are generally undetectable clinically. Atropine does…

Indications (2)

older for: Atropine is an anticholinergic agent indicated in adults

Worked on DI-ATRO at NMD Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.